A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Intellia Therapeutics Inc’s current trading price is -57.18% away from its 52-week high, while its distance from the 52-week low is 75.34%. The stock’s price range for this time frame has been between $5.90 and $24.16. The trading volume of the company’s shares in the Healthcare reached around 2.3 million for the day, which was evidently lower than the average daily volume of 5.18 million over the last three months.
The current stock price for Intellia Therapeutics Inc (NTLA) is $10.35. The stock experienced a significant increase during the last trading session, reaching $106.0 after opening at $10.26. It dipped to a low of $7.0 before ultimately closing at $10.73.
In terms of market performance, Intellia Therapeutics Inc had a somewhat inconsistent run in. The highest value for the stock in the past year was $24.16 on 08/23/24, while the lowest value was $5.90 on 04/07/25.
How Financial Performance Impacts Market Capitalization
Intellia Therapeutics Inc (NTLA) has experienced a quarterly rise of 14.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.11B and boasts a workforce of 403 employees.
Decoding Analysts’ Ratings for Intellia Therapeutics Inc
As of right now, 18 analysts are rating Intellia Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 9.41, with a change in price of +1.90. Similarly, Intellia Therapeutics Inc recorded 4,564,144 in trading volume during the last 100 days, posting a change of +22.92%.
How NTLA’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for NTLA stands at 0.14. Similarly, the long-term debt-to-equity ratio is also 0.11.
NTLA Stock Stochastic Average
The raw stochastic average for Intellia Therapeutics Inc over the last 50 days is presently at 33.51%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 0.79%. Further, the company’s Stochastic %K and %D values for the last 20 days were 5.05% and 7.43%, respectively.
NTLA Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant loss of -54.77% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -10.28%. Over the past 30 days, the price of NTLA has leaped by -18.09%. And in the last five days, it has fallen by -4.74%.
